Conserving Drug Product to Treat More Patients: De-risking CGT Therapies Early in Process Development for Late-Stage Success and Savings

Compared to previous drug modalities, the cell and gene therapy space experiences both faster development and more accelerated clinical trial timelines. This pace has resulted in a paradigm in which many companies attempt to circumvent some of the more in-depth aspects of process development to save time and reach the clinic faster. This approach frequently results in risks associated with limited drug product understanding, undermining its ultimate availability and jeopardizing commercial success….

Read the full article on Cell&Gene.com

In need of immediate assistance for your product development? Contact us here or simply call to speak with a CBM expert: 866-274-4009.